Semaglutide-Associated Acute Interstitial Nephritis: A Case Report

Kidney Med. 2022 Oct 29;4(12):100561. doi: 10.1016/j.xkme.2022.100561. eCollection 2022 Dec.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). These agents have proven benefits on cardiac outcomes and all-cause mortality as well as in reducing the incidence of macroalbuminuria. Ours is a case of drug-associated acute interstitial nephritis requiring hemodialysis temporally related to a semaglutide dose increase. This case is unique as the index patient had no underlying CKD. Limited cases of acute kidney injury, superimposed on underlying CKD, in patients taking the GLP-1RA semaglutide have been reported. To our knowledge, there are no existing case reports in the literature of GLP-1RA-associated acute interstitial nephritis in a patient with baseline normal kidney function. Because our prescription of these agents is increasing and is anticipated to increase further with growing scientific evidence for their benefit, we sought to highlight this possible, important serious adverse effect of semaglutide.

Keywords: Acute interstitial nephritis; acute kidney injury; glucagon-like peptide 1 receptor agonists; semaglutide.

Publication types

  • Case Reports